SBIR/STTR Research Award
Analysis of Circulating Cancer Cells Early in Disease
Award amount
$309,500Program and phase
SBIR · Phase IIAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Immunicon Corporation
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION: (provided by applicant)
The long term objective of this proposal is commercialization of a test for
the management of cancer. Immunicon has developed a sensitive test for
detecting tumor cells in peripheral blood. This test uses ferrofluids and
magnetic separation technology for tumor cell enrichment and multidimensional
flow cytometry for cell analysis. Clinical data show that tumor cells exist
in the blood of breast cancer patients. One limitation of this test is that
flow cytometry does not confirm the identity of the events that are detected.
Morphologic features of cells of immunophenotypically identified events can
improve the specificity of the test. These features can be obtained using
multicolor fluorescent microscopy. The quantity of ferrofluid used to
capture tumor cells from blood, however, can obscure the cell. Phase I
feasibility data show that proposed new methods helped to decrease ferrofluid
without sacrificing the sensitivity of the test and the proposed objectives
were achieved. Feasibility data also shows that incorporating these methods
into new assay procedures permits microscopy analysis - a significant
breakthrough. The aim of this Phase II proposal is to adapt these new
procedures which incorporate the Phase I developments to further develop and
validate the test to detect cancer cells present in blood using multi color
fluorescent microscopy.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
Technology keywords
Not reported